Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Hypertension Monotherapy or in combination with other antihypertensive agents: As levamlodipine maleate/besylate: Initial: 2.5 mg once daily. Angina pectoris As levamlodipine besylate: 2.5 mg once daily. All doses may be increased as necessary according to patient response. Max: 5 mg once daily.
Special Precautions
Patient with severe aortic stenosis; severe obstructive coronary artery disease, heart failure with reduced ejection fraction, hypertrophic cardiomyopathy and outflow tract obstruction. Hepatic impairment. Children and elderly. Pregnancy and lactation. Monitoring Parameters Monitor heart rate and blood pressure.
Adverse Reactions
Significant: Worsening angina, acute MI, reflex tachycardia, symptomatic hypotension. Cardiac disorders: Dyspnoea, palpitation. Gastrointestinal disorders: Nausea, abdominal pain. General disorders and administration site conditions: Fatigue, asthenia. Hepatobiliary disorders: Jaundice. Investigations: Increased liver enzymes. Metabolism and nutrition disorders: Peripheral oedema. Musculoskeletal and connective tissue disorders: Muscle cramps. Nervous system disorders: Dizziness, extrapyramidal disorder. Psychiatric disorders: Somnolence, insomnia. Reproductive system and breast disorders: Sexual dysfunction, gynaecomastia. Skin and subcutaneous tissue disorders: Rash, pruritus. Vascular disorders: Flushing.
Drug Interactions
May increase serum concentrations with moderate and strong CYP3A4 inhibitors. May increase the serum levels of simvastatin, lovastatin, immunosuppressants (e.g. ciclosporin, tacrolimus).
Disclaimer: This information is independently developed by CIMS based on levamlodipine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in